Study Summary
Evaluation of the efficacy and safety of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of recurrent or refractory CD22 positive B cell acute lymphoblastic leukemia (B-ALL)
Want to learn more about this trial?
Request More InfoInterventions
Autologous chimeric antigen receptor T cell transfusing agent targeting CD22DRUG
The enrolled patients will receive autologous-derived CD22-targeted CAR-T cells in 1 day with 100% of the total expected dosage after receiving lymphodepleting chemotherapy
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| PersonGen·Anke cellular therapeutics Co., Ltd | Hefei | Anhui | China |